<prompt> A patient presented with pulmonary embolism the treatment to be given isUrokinase with fibrinolyticsi.v. Heparin with continuous infusion followed by coumarin for 4-5 monthsSubcutaneous Heparin 5000 unitsWarfarin with INR 1-1.5  <response>: B i.v. Heparin with continuous infusion followed by coumarin for 4-5 months Thrombolysis: Successful thrombolytic therapy rapidly reverses right heart failure and leads to a lower rate of death and recurrent PE. Thrombolysis usually: Dissolves much of the anatomically obstructing pulmonary arterial thrombus; Prevents the continued release of serotonin and other neurohumoral factors that exacerbate pulmonary hypertension; and Dissolves much of the source of the thrombus in the pelvic or deep leg veins, thereby decreasing the likelihood of recurrent PE. The preferred thrombolytic regimen is 100 mg of recombinant tissue plasminogen activator tPA administered as a continuous peripheral intravenous infusion over 2 h. Patients appear to respond to thrombolysis for up to 14 days after the PE has occurred. Contraindications to thrombolysis include intracranial disease, recent surgery, or trauma. There is a 1 to 2 risk of intracranial hemorrhage. Careful screening of patients for contraindications to thrombolysis is the best way to minimize bleeding risk. 